hnRNPA1 Cancer Research Results

hnRNPA1, Heterogeneous nuclear ribonucleoprotein A: Click to Expand ⟱
Source:
Type:
Heterogeneous nuclear ribonucleoprotein A/B (hnRNPA/B) is one of the core members of the RNA binding protein (RBP) hnRNPs family, including four main subtypes, A0, A1, A2/B1 and A3, which share the similar structure and functions.
hnRNPA1 was highly expressed in gastric cancer tissues, which promote proliferation, migration and EMT of gastric cancer cells. Down-regulation of HNRNPA1 could suppress tumorigenesis by cell cycle arrest or by inducing apoptosis in cancer cells.

Oncogenic Potential:
hnRNPA1 has been shown to have oncogenic properties in certain contexts, promoting cell proliferation and survival.
Its dysregulation can lead to alternative splicing events that contribute to cancer progression and metastasis.

Its overexpression is associated with various cancers, including breast, lung, colorectal, and prostate cancers, often correlating with poor prognosis and aggressive tumor behavior. As a potential therapeutic target and biomarker, hnRNPA1 represents an important area of research in oncology.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
93- QC,    Chemical Proteomics Identifies Heterogeneous Nuclear Ribonucleoprotein (hnRNP) A1 as the Molecular Target of Quercetin in Its Anti-cancer Effects in PC-3 Cells
- in-vitro, Pca, PC3
hnRNPA1↓, Casp3↑, Casp7↑, TumCD↑, IAP1↓,
75- QC,  ENZ,    Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells
- in-vitro, Pca, HEK293 - in-vitro, NA, 22Rv1 - in-vitro, NA, C4-2B
hnRNPA1↓, PSA↓, NKX3.1↓, FKBP5↓, UBE2C↓, AR-FL↓, AR-V7↑, AR↓, eff↑, TumVol↓, BioAv↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Casp3↑, 1,   Casp7↑, 1,   IAP1↓, 1,   TumCD↑, 1,  

DNA Damage & Repair ⓘ

NKX3.1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

AR-FL↓, 1,   AR-V7↑, 1,  

Migration ⓘ

hnRNPA1↓, 2,  

Immune & Inflammatory Signaling ⓘ

PSA↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   FKBP5↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

TumVol↓, 1,   UBE2C↓, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: hnRNPA1, Heterogeneous nuclear ribonucleoprotein A
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:388  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page